BE Study of Fluticasone Propionate/Salmeterol Inhalation Powder in Asthma Patients

NCT ID: NCT03394989

Last Updated: 2020-08-13

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 1366 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-10-17
• Study Completion Date: 2020-03-31

Brief Summary

The purpose of this study is to demonstrate the pharmacodynamic bioequivalence of the test product to the reference product in adult patients with asthma.

Detailed Description

This study is to demonstrate the pharmacodynamic bioequivalence of the test product to the reference product in terms of FEV1 measured at different time-points in adult patients with asthma.

Conditions

Bronchial Asthma

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Test

Fluticasone propionate/salmeterol 100/50 µg

Group Type: EXPERIMENTAL

Fluticasone propionate/salmeterol 100/50 µg

Intervention Type: DRUG

Test Arm: Dry powder inhaler

Comparator

Fluticasone propionate/salmeterol 100/50 µg

Group Type: ACTIVE_COMPARATOR

Advair Diskus 100/50 Dry Powder Inhaler, 60 ACTUAT

Intervention Type: DRUG

Comparator Arm: Dry powder inhaler

Placebo

Test Placebo

Group Type: OTHER

Placebo

Intervention Type: OTHER

Placebo

Interventions

Fluticasone propionate/salmeterol 100/50 µg

Test Arm: Dry powder inhaler

Intervention Type: DRUG

Placebo

Placebo

Intervention Type: OTHER

Advair Diskus 100/50 Dry Powder Inhaler, 60 ACTUAT

Comparator Arm: Dry powder inhaler

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Patients who have signed informed consent form before initiation of any study related procedure.

2. Male or female patients who are ≥18 years of age at the time informed consent is obtained.

3. Documented diagnosis of asthma as defined by the National Asthma Education and Prevention Program (NAEPP) and diagnosed at least 12 weeks prior to screening.

4. Patients with pre-bronchodilator forced expiratory volume in one second (FEV1) of 40% to 85% (both inclusive) of the predicted normal value at the Screening Visit V2.

5. Patients who demonstrated an increase of ≥15% of FEV1 within 15 30 minutes following administration of albuterol at Screening Visit V2

6. Patients who are stable on current asthma treatment for at least 4 weeks prior to Screening Visit V1.

7. Patients who are able to discontinue their current asthma medications (if any) and any other prohibited medications throughout the study, per the protocol list of prohibited medications during study participation (see Section 6.3.2).

8. Patients who are able to replace their current short-acting beta 2 agonist (SABA) inhaler with the study provided albuterol inhaler to be used as rescue medicine (as needed) throughout the study. Patients who are able to withhold SABAs for at least 6 hours prior to lung function assessments on study visits.

9. Patient who are non-smokers or ex-smokers; and have had ≤10 pack years

10. Patients who have not inhaled tobacco or consumed other tobacco containing products have not inhaled vaping products, drugs of abuse, or inhaled marijuana for at least 12 months prior to screening.

11. Women of childbearing potential (WOCBP) must not be lactating or pregnant at screening, as documented by a negative screening pregnancy test

12. Women of childbearing potential must commit to consistent and correct use of an acceptable method of birth control (at the investigator's discretion) throughout the study.

Exclusion Criteria

1. History of life-threatening asthma defined as an asthma episode(s) that required intubation and/or was associated with hypercapnic, respiratory arrest, or hypoxic seizures, asthma related syncopal episode(s) within the past one year.

2. History of any asthma-related hospitalizations within the past one year.

3. Any asthma exacerbation requiring emergency room (ER) visits or systemic (including oral) corticosteroids within 2 months prior to signing the consent.

4. Evidence or history of clinically significant disease or abnormality including congestive heart failure, uncontrolled hypertension, uncontrolled coronary artery disease, myocardial infarction, or cardiac dysrhythmia (prolonged QT interval as judged by the investigator). In addition, historical or current evidence of significant hematologic, hepatic neurologic, psychiatric, renal, or other diseases that in the opinion of the investigator, would put the patient at risk through study participation, or would affect the study analyses if the disease exacerbated during the study.

5. Patients with uncontrolled allergic rhinitis.

6. Clinical visual evidence of oral candidiasis.

7. History of any adverse reaction; known hypersensitivity to any sympathomimetic drug

8. Use of medication(s) with potential to affect the course of asthma or to interact with sympathomimetic amines throughout the study period.

9. Recent viral or bacterial infection or infection of the upper or lower respiratory tract, sinus, or middle ear that is not resolved within 4 weeks of screening.

10. Patients, who in the opinion of the investigator, significantly abuse alcohol or drugs will be excluded.

12. Patients taking any immunosuppressive medications within 4 weeks prior to screening and during the study.

13. Factors (e.g., infirmity, disability, geographic location) that the investigator felt would likely limit the patients' compliance with the study protocol or scheduled clinic visits.

14. Use of any investigational drug (approved or unapproved) within 30 days

15. Study participation by clinical investigator site employees and/or their immediate relatives.

16. Patients who are unable to produce valid and reproducible spirometry per American Thoracic Society/European Respiratory Society (ATS/ERS) standards at the screening visit or unable to use the electronic diary (e diary).

17. Patients unable to use the inhalation powder device adequately.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Cipla Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Combined Research Orlando

Orlando, Florida, United States

Countries

United States

Other Identifiers

U-FS-MU-AS3120

Identifier Type: -

Identifier Source: org_study_id